BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex Ventures...
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...converted into a pivotal trial.Inmagene adds $21M in series BShanghai-based Inmagene Biopharmaceuticals Co. Ltd. said Vertex Ventures...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS).Vertex Ventures...
...Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Relmada Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

...with participation from SR One, Pfizer Ventures, Vertex Ventures...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...Pharmaceuticals Inc. (NASDAQ:MACK), as well as a $32.5 million series A round led by Aisling. Vertex Ventures...
...Caris Life Sciences Inc. Number of employees: 5 Funds raised: $32.5 million Investors: Aisling Capital, Vertex Ventures...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...initial close of a series A round led by Debiopharm's venture capital fund. Existing investors Vertex Ventures...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...new investors co-leading its series B round were The Invus Group, Surveyor Capital, EDBI and Vertex Ventures...
BioCentury | Dec 18, 2019
Financial News

With new name, Epirium snags $85M series A to develop hormonal therapy for muscular dystrophies

...as human proof-of-concept data for its lead candidate in muscular dystrophies. BlueBird Ventures, Adams Street, Vertex Ventures...
BioCentury | Sep 20, 2019
Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...Venture Capital, Boxer Capital of the Tavistock Group, City Hill Ventures, GT Healthcare Capital Partners, Vertex Ventures...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...Funds raised: $82.8 million Investors: MPM Capital, Novartis Venture Fund, Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures...
Items per page:
1 - 10 of 37
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex Ventures...
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...converted into a pivotal trial.Inmagene adds $21M in series BShanghai-based Inmagene Biopharmaceuticals Co. Ltd. said Vertex Ventures...
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...the Treasury office responsible for chairing the Committee on Foreign Investment in the United States (CFIUS).Vertex Ventures...
...Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Relmada Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision Inc. Vertex Ventures...
BioCentury | Sep 18, 2020
Finance

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

...with participation from SR One, Pfizer Ventures, Vertex Ventures...
BioCentury | Jul 23, 2020
Finance

Elevation debuts with tumor-agnostic mAb in Phase II

...Pharmaceuticals Inc. (NASDAQ:MACK), as well as a $32.5 million series A round led by Aisling. Vertex Ventures...
...Caris Life Sciences Inc. Number of employees: 5 Funds raised: $32.5 million Investors: Aisling Capital, Vertex Ventures...
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...initial close of a series A round led by Debiopharm's venture capital fund. Existing investors Vertex Ventures...
BioCentury | Mar 30, 2020
Finance

ElevateBio raises $170M, plans additions to portfolio with six clinical programs by 2021

...new investors co-leading its series B round were The Invus Group, Surveyor Capital, EDBI and Vertex Ventures...
BioCentury | Dec 18, 2019
Financial News

With new name, Epirium snags $85M series A to develop hormonal therapy for muscular dystrophies

...as human proof-of-concept data for its lead candidate in muscular dystrophies. BlueBird Ventures, Adams Street, Vertex Ventures...
BioCentury | Sep 20, 2019
Emerging Company Profile

Boundless Bio: designing cancer therapies around extrachromosomal DNA

...Venture Capital, Boxer Capital of the Tavistock Group, City Hill Ventures, GT Healthcare Capital Partners, Vertex Ventures...
BioCentury | Jul 11, 2019
Emerging Company Profile

Twentyeight-Seven’s bet on RNA-binding proteins

...Funds raised: $82.8 million Investors: MPM Capital, Novartis Venture Fund, Johnson & Johnson Innovation-JJDC Inc., Vertex Ventures...
Items per page:
1 - 10 of 37